Stock listing

Outlook Therapeutics, Inc.

Selected listing: 41O · MUN · EUR · DE

Outlook Therapeutics, Inc. (Munich:41O), Health Technology. Latest release Oct 6, 2026: Outlook Therapeutics Highlights What the Appointment of New CFO Kevin…

41O:MUNEURDEUpdated October 2, 2026

Ticker: Munich:41O
Asset type: Stock
Sector: Health Technology
Industry: Pharmaceuticals: Major
Exchange: Munich
Currency: EUR

Latest news from Outlook Therapeutics, Inc.

Outlook Therapeutics Highlights What the Appointment of New CFO Kevin Lundquist Means for the Company’s Next Chapter in Virtual Investor Discussion

October 6, 2026

Outlook Therapeutics Submits HCPCS Level II Application to CMS for Permanent J-Code for LYTENAVA™ (bevacizumab-vikg)

October 1, 2026

Outlook Therapeutics Submits HCPCS Level II Application to CMS for Permanent J-Code for LYTENAVA™ (bevacizumab-vikg)

September 30, 2026

Outlook Therapeutics Fireside Chat from H.C. Wainwright Conference Now Available On-Demand

September 11, 2026

Outlook Therapeutics CEO, Bob Jahr, Discusses FDA Approval and Commercial Opportunity for LYTENAVA™ in Virtual Investor CEO Connect Segment

September 10, 2026

All Outlook Therapeutics, Inc. news →

Events

Replays

Outlook Therapeutics, Inc. (OTLK) Q3 2026 Earnings Call
Fri, Aug 14, 2026 · 08:30 AM ET
Watch
Outlook Therapeutics, Inc. (OTLK) Q3 2024 Earnings Call
Wed, Aug 14, 2024 · 08:30 AM ET
Watch
Outlook Therapeutics, Inc. (OTLK) Q2 2024 Earnings Call
Thu, May 16, 2024 · 08:30 AM ET
Watch

Research Outlook Therapeutics, Inc.

Outlook Therapeutics, Inc. company profile

View the public company page for Outlook Therapeutics, Inc. on 6ix.

Outlook Therapeutics, Inc. news

Read company news and market updates connected to Outlook Therapeutics, Inc..

Outlook Therapeutics, Inc. investor events

Find investor webinars, events, and replay context for Outlook Therapeutics, Inc..